KIT mutations confer a distinct gene expression signature in core binding factor leukaemia.
about
Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-AnalysisThe cnidarian origin of the proto-oncogenes NF-κB/STAT and WNT-like oncogenic pathway drives the ctenophores (Review)A novel melting curve-based method for detecting c-kit mutations in acute myeloid leukemia.Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Trisomy 11 as an isolated abnormality in acute myeloid leukemia is associated with unfavorable prognosis but not with an NPM1 or KIT mutation.Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations.inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers.Gene expression profiling in MDS and AML: potential and future avenues.New agents for acute myeloid leukemia: is it time for targeted therapies?Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups.KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia.Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair.Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta.
P2860
Q26771740-75ADCDA3-2755-41BB-AE58-9B284C4C8AD0Q26799398-0B729D00-B29F-492D-BC7F-894AD9E752FAQ33778329-848F514B-79DD-4FF0-A147-2B9AAE2C1F1AQ34663691-ACF4215D-DBDB-452E-AD63-9CC8F34F9095Q34976428-CE54CBCE-D818-4406-85DA-F5DD3B02B15CQ35606252-40B55082-8B77-41D9-8826-962ADFA091E8Q35776442-824CDE89-8ABA-49A7-B13A-10CF5452CE39Q35849281-32F7D8BA-9EA3-4EBC-A04C-3622794A45E7Q36529502-150597F7-A184-42E1-B8B9-805436DB87E2Q37580273-24426311-D057-4D6D-A191-ABED1F974E96Q37858877-AC505CD3-438B-418D-93C3-1EF9CC4B373CQ37973135-8CE0EA77-2BC7-4AF0-9020-EC6DD565AEC2Q38263126-86EAEC9A-8A2F-4ED1-9964-C6608928DE17Q38333998-C1EABD64-8496-4FB5-B0F8-9F2B0804DC93Q38457561-7BC3546A-E60B-4C2C-89B8-5A631E68C141Q39438493-85E38FB2-6679-4F0E-B014-EEEB1244182EQ41973082-5B8C0A00-E6D6-42D5-89DB-5E2B548619C6Q46515733-09B3BBCF-5CC4-4148-AC9C-8D02ACE180B2Q46711978-FC511145-9082-44A4-9618-5F0800D4D338Q47109059-3ED473CD-A136-415B-967D-514473246DBBQ51039848-93ECAD7D-05DE-4F38-AA9C-7ADC14849C27
P2860
KIT mutations confer a distinct gene expression signature in core binding factor leukaemia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
KIT mutations confer a distinc ...... core binding factor leukaemia.
@en
type
label
KIT mutations confer a distinc ...... core binding factor leukaemia.
@en
prefLabel
KIT mutations confer a distinc ...... core binding factor leukaemia.
@en
P2093
P50
P1476
KIT mutations confer a distinc ...... core binding factor leukaemia.
@en
P2093
Annika C Russ
Lars Bullinger
Richard F Schlenk
Sonja C Lück
Verena Gaidzik
P304
P356
10.1111/J.1365-2141.2009.08035.X
P407
P577
2010-01-08T00:00:00Z